Dec 03, 2019
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications
Nov 21, 2019
AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting
Nov 21, 2019
FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia
Nov 08, 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Nov 08, 2019
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
Nov 08, 2019
BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019
Nov 06, 2019
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
Nov 04, 2019
Ascentage Pharma and Henlius Form a Combination Therapy Strategic Collaboration
Oct 08, 2019
Health Canada approves CALQUENCE® (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)
Oct 03, 2019
MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
Aug 08, 2019
Having a Parent, Sibling, or Child with Blood Cancer Increases One's Own Risk
Jul 16, 2019
Ublituximab Drug Overview 2019: An Anti-CD20 Monoclonal Antibody, Currently in Late-Stage Trials Across a Range of Hematological and Neurological Indications
Jul 12, 2019
Global Treanda (bendamustine; Teva/Mundipharma/Eisai Drug Overview & Product Profiles 2017-2026
Jul 12, 2019
Arzerra Drug Overview 2019: A Fully Human Immunoglobulin G1 and High-Affinity Antibody that Targets a Novel Epitope on Cluster of Differentiation 20 (CD20) on the B-Cell Membrane
Jul 12, 2019
Zydelig (idelalisib; Gilead) Drug Overview 2019: An Oral, Highly Selective Inhibitor of the Phosphoinositide 3-Kinase (PI3K) Isoform p110-delta
Jul 09, 2019
Venclexta (venetoclax; AbbVie/Roche) Drug Overview & Product Profile 2017-2026: A Novel B-Cell Lymphoma 2 (BCL-2) Inhibitor that Received an Accelerated US FDA Approval
Jul 08, 2019
Calquence (acalabrutinib; AstraZeneca/Acerta) Markets, 2017-2026: A Novel, Orally Available, Second-Generation Bruton's Tyrosine Kinase Inhibitor with Potential Antineoplastic Activity
Jul 08, 2019
Zanubrutinib (BeiGene) Drug Overview and Product Profiles 2017-2026
Jul 08, 2019
Copiktra (Duvelisib; Verastem/Yakult Honsha) Drug Overview & Product Profiles 2017-2026
Jun 26, 2019
Kymriah (tisagenlecleucel; Novartis) Drug Profile 2019: A Cluster of Differentiation (CD)19-Targeted Genetically Modified Autologous T-cell Immunotherapy